Immunocompromised Patients Clinical Trial
Official title:
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Patients at High Risk of Severe Forms of Covid-19
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients. Being at high risk of a severe form of Covid-19, they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies (mAbs). This study aims to describe patients who received anti-SARS-CoV-2 mAbs, in prophylaxis and/or curative of covid-19, and to analyze the hospitalization and mortality rates. This study is multicentric on all the university hospitals of Paris (AP-HP).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05605145 -
PCP in Immunocompromised Population in Southern China
|
||
| Recruiting |
NCT05726006 -
Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.
|
||
| Not yet recruiting |
NCT04680884 -
Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial
|
Phase 3 | |
| Not yet recruiting |
NCT02983851 -
Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure
|
N/A | |
| Completed |
NCT01218685 -
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
|
N/A | |
| Completed |
NCT04805125 -
Immunocompromised Swiss Cohorts Based Trial Platform
|
Phase 3 |